{"id":904153,"date":"2025-11-03T09:39:37","date_gmt":"2025-11-03T14:39:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/"},"modified":"2025-11-03T09:39:37","modified_gmt":"2025-11-03T14:39:37","slug":"sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/","title":{"rendered":"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025.<\/p>\n<p>\u201cWe look forward to presenting new preclinical data at this year\u2019s World ADC conference that underscore the breadth of innovation emerging from Sutro\u2019s platform and the meaningful progress we\u2019re making toward advancing the next-generation of ADCs,\u201d said Hans-Peter Gerber, Sutro\u2019s Chief Scientific Officer. \u201cAmong the highlights, we\u2019re excited to share results demonstrating how our dual-payload ADCs, including immunostimulatory ADCs, can potentially redefine treatment paradigms by enhancing therapeutic index and addressing tumor resistance\u2014two of the biggest challenges in oncology today. Together with our unique cell-free platform, these advances reinforce Sutro\u2019s leadership in ADC innovation and our commitment to driving long-term value through transformative science.\u201d\u00a0<\/p>\n<p>\n        <strong>Presentation\/Panel Discussion Details:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Showcasing Development of Site-Specific, High-DAR Dual-Payload ADCs<\/strong><\/p>\n<ul type=\"circle\">\n<li>Presenter: Daniel Calerese, Ph.D.<\/li>\n<li>Date\/Time: November 3, 2025, 12:00PM PT<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Developing Next-Generation Immunostimulatory Dual Payload ADCs to Enhance Therapeutic Index &amp; Tackle Patient Resistance<\/strong><br \/>\n          <\/p>\n<ul type=\"circle\">\n<li>Presenter: Gang Yin, Ph.D.<\/li>\n<li>Date\/Time: November 3, 2025, 12:30PM PT<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Exploring Supply Chain &amp; CMC Advantages of Cell-Free Antibody Manufacturing to Design &amp; Produce Unique ADCs<\/strong><br \/>\n          <\/p>\n<ul type=\"circle\">\n<li>Presenter: Venkatesh Srinivasan, Ph.D.<\/li>\n<li>Date\/Time: November 4, 2025, 11:00AM PT<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Panel Discussion: Delving into Novel Design &amp; Development to Strive for Next-Generation ADCs Providing Long-Term Benefit to Patients<\/strong><br \/>\n          <\/p>\n<ul type=\"circle\">\n<li>Sutro Participant: Hans-Peter Gerber, Ph.D.<\/li>\n<li>Date\/Time: November 4, 2025, 5:00PM PT<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Developing Site-Specific Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms<\/strong><br \/>\n          <\/p>\n<ul type=\"circle\">\n<li>Presenter: Krishna Bajjuri, Ph.D.<\/li>\n<li>Date\/Time: November 5, 2025, 11:00AM PT<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Panel Discussion: The Way Forward: What\u2019s the New Path to the Next-Generation of ADCs?<\/strong><br \/>\n          <\/p>\n<ul type=\"circle\">\n<li>Sutro Participant: Daniel Calarese, Ph.D.<\/li>\n<li>Date\/Time: November 5, 2025, 12:30PM PT<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Laying Out Discovery &amp; Development of STRO-006: A Differentiated Topo1-ADC Targeting Integrin Beta-6<\/strong><br \/>\n          <\/p>\n<ul type=\"circle\">\n<li>Presenter: Alice Yam, Ph.D.<\/li>\n<li>Date\/Time: November 5, 2025, 2:00PM PT<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Summary Panel Discussion: What is Showing the Most Promise &amp; What Still Needs to be Proven in ADC Chemistry Innovation?<\/strong><br \/>\n          <\/p>\n<ul type=\"circle\">\n<li>Sutro Participant: Hans-Peter Gerber, Ph.D.<\/li>\n<li>Date\/Time: November 5, 2025, 3:00PM PT<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Following the event, the content will be made available in the Clinical\/Scientific Presentation and Publication Highlights section of Sutro Biopharma\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y56W073fiHrvzB-oyp7tistIYIbCzAoeXc7_4p3J2JxfNagPMkGa4Ga7OwNTU4XqoYFWKQv3KlEWwn_Cc6vRcZTpozkB6F-l0BUN-o9FmTI=\" rel=\"nofollow\" target=\"_blank\">www.sutrobio.com<\/a>.<\/p>\n<p>\n        <strong>About Sutro Biopharma \u00a0<\/strong><br \/>\n        <br \/>Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro\u2019s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what\u2019s possible in cancer therapy. The Company\u2019s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.<\/p>\n<p>For more information, follow Sutro on social media @Sutrobio or visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y56W073fiHrvzB-oyp7tih3keNWD05mu5SBFAwzMCt6CoWm6cuoupZtAp_KSAIQSJeQClbba3wwACx58xcSY2A8OErerRKCuuNag78ioSl0=\" rel=\"nofollow\" target=\"_blank\"><u>www.sutrobio.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities; timing of announcements of IND submissions, clinical results, trial initiation, and other regulatory filings; outcome of discussions with regulatory authorities; potential benefits of the Company\u2019s product candidates and platform; and potential market opportunities for the Company\u2019s product candidates; . All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company\u2019s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company\u2019s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company\u2019s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company\u2019s ability to fund development activities and achieve development goals, the Company\u2019s ability to protect intellectual property, and the Company\u2019s commercial collaborations with third parties and other risks and uncertainties described under the heading \u201cRisk Factors\u201d in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzY5ODk5N2UtM2MyMy00OTUzLWJmOWYtNDgwMjA4ODU0ZDQ4LTExMzUzMzUtMjAyNS0xMS0wMy1lbg==\/tiny\/Sutro-Biopharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact\r\nEmily White\r\nSutro Biopharma\r\n(650) 823-7681\r\newhite@sutrobio.com\r\n\r\nMedia Contact\r\nAmy Bonanno\r\nLyra Strategic Advisory\r\nabonanno@lyraadvisory.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025. \u201cWe look forward to presenting new preclinical data at this year\u2019s World ADC conference that underscore the breadth of innovation emerging from Sutro\u2019s platform and the meaningful progress we\u2019re making toward advancing the next-generation of ADCs,\u201d said Hans-Peter Gerber, Sutro\u2019s Chief Scientific Officer. \u201cAmong the highlights, we\u2019re excited to share results demonstrating how our dual-payload ADCs, including immunostimulatory ADCs, can potentially redefine treatment paradigms by enhancing therapeutic index and addressing tumor &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904153","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025. \u201cWe look forward to presenting new preclinical data at this year\u2019s World ADC conference that underscore the breadth of innovation emerging from Sutro\u2019s platform and the meaningful progress we\u2019re making toward advancing the next-generation of ADCs,\u201d said Hans-Peter Gerber, Sutro\u2019s Chief Scientific Officer. \u201cAmong the highlights, we\u2019re excited to share results demonstrating how our dual-payload ADCs, including immunostimulatory ADCs, can potentially redefine treatment paradigms by enhancing therapeutic index and addressing tumor &hellip; Continue reading &quot;Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T14:39:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference\",\"datePublished\":\"2025-11-03T14:39:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/\"},\"wordCount\":846,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/\",\"name\":\"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=\",\"datePublished\":\"2025-11-03T14:39:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/","og_locale":"en_US","og_type":"article","og_title":"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025. \u201cWe look forward to presenting new preclinical data at this year\u2019s World ADC conference that underscore the breadth of innovation emerging from Sutro\u2019s platform and the meaningful progress we\u2019re making toward advancing the next-generation of ADCs,\u201d said Hans-Peter Gerber, Sutro\u2019s Chief Scientific Officer. \u201cAmong the highlights, we\u2019re excited to share results demonstrating how our dual-payload ADCs, including immunostimulatory ADCs, can potentially redefine treatment paradigms by enhancing therapeutic index and addressing tumor &hellip; Continue reading \"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T14:39:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference","datePublished":"2025-11-03T14:39:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/"},"wordCount":846,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/","name":"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=","datePublished":"2025-11-03T14:39:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM0NCM3MjM3MDIzIzIxMjM3NjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904153"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904153\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}